67 related articles for article (PubMed ID: 2125235)
1. Tissue-type plasminogen activator alone or in combination with thromboxane A2 synthetase inhibitor for ischemic myocardium.
Ogawa T; Miura T; Tsuchida A; Iwamoto T; Urabe K; Endoh A; Iimura O
Can J Cardiol; 1990 Oct; 6(8):361-6. PubMed ID: 2125235
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of thromboxane A2 synthetase failed to limit myocardial infarct size in a rabbit ischemia-reperfusion model.
Tsuchida A; Miura T; Ogawa T; Iwamoto T; Shimamoto K; Iimura O
Jpn Circ J; 1991 Feb; 55(2):174-83. PubMed ID: 2020088
[TBL] [Abstract][Full Text] [Related]
3. Effect of superoxide dismutase plus catalase on myocardial infarct size in rabbits.
Miura T; Downey JM; Hotta D; Iimura O
Can J Cardiol; 1988; 4(8):407-11. PubMed ID: 3228770
[TBL] [Abstract][Full Text] [Related]
4. [The safety and efficacy of systemic salvage thrombolysis in acute myocardial infarct].
Sarullo FM; Schicchi R; Schirò M; Americo L; Bonnì G; Faraone N; Di Pasquale P; Castello A; Mauri F
Ital Heart J Suppl; 2000 Jan; 1(1):81-7. PubMed ID: 10832123
[TBL] [Abstract][Full Text] [Related]
5. Endogenous nitric oxide (NO) protects against ischaemia-reperfusion injury in the rabbit.
Williams MW; Taft CS; Ramnauth S; Zhao ZQ; Vinten-Johansen J
Cardiovasc Res; 1995 Jul; 30(1):79-86. PubMed ID: 7553727
[TBL] [Abstract][Full Text] [Related]
6. [t-PA in thrombolytic therapy of acute myocardial infarct].
Rutsch W; Schmutzler H
Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of myocardial salvage by tissue type plasminogen activator in combination with a thromboxane synthetase inhibitor in ischemic cat myocardium.
Lefer AM; Mentley R; Sun JZ
Circ Res; 1988 Sep; 63(3):621-7. PubMed ID: 3136950
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotective effects of the novel adenosine A1/A2 receptor agonist AMP 579 in a porcine model of myocardial infarction.
Smits GJ; McVey M; Cox BF; Perrone MH; Clark KL
J Pharmacol Exp Ther; 1998 Aug; 286(2):611-8. PubMed ID: 9694911
[TBL] [Abstract][Full Text] [Related]
9. Reduction of infarct size and infiltration of polymorphonuclear leukocytes by a thromboxane synthetase inhibitor. Studies in a rabbit ischemic heart model.
Ito T; Asai F; Ushiyama S; Matsuda K; Oshima T
Arzneimittelforschung; 1990 Jan; 40(1):23-7. PubMed ID: 1692704
[TBL] [Abstract][Full Text] [Related]
10. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
[TBL] [Abstract][Full Text] [Related]
11. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion.
Kolh P; Rolin S; Tchana-Sato V; Pétein M; Ghuysen A; Lambermont B; Hanson J; Magis D; Segers P; Masereel B; D'Orio V; Dogne JM
Prostaglandins Other Lipid Mediat; 2006 Mar; 79(1-2):53-73. PubMed ID: 16516810
[TBL] [Abstract][Full Text] [Related]
13. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator.
Huber K; Beckmann R; Rauscha F; Probst P; Kaindl F; Binder BR
Z Kardiol; 1993; 82 Suppl 2():195-200. PubMed ID: 8328203
[TBL] [Abstract][Full Text] [Related]
14. Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs.
Vander Heide RS; Reimer KA
Cardiovasc Res; 1996 May; 31(5):711-8. PubMed ID: 8763400
[TBL] [Abstract][Full Text] [Related]
15. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
Shebuski RJ; Smith JM; Storer BL; Granett JR; Bugelski PJ
J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
[TBL] [Abstract][Full Text] [Related]
16. [The protective effect of interleukin-1 receptor antagonist on postischemic reperfused myocardium and its possible mechanism].
Li YJ; Ding WH; Gao W; Huo Y; Hong T; Zhu RY; Ma DL
Zhonghua Yi Xue Za Zhi; 2004 Apr; 84(7):548-53. PubMed ID: 15144587
[TBL] [Abstract][Full Text] [Related]
17. Effect of a novel thromboxane A2 synthetase inhibitor on ischemia-induced mitochondrial dysfunction in canine hearts.
Ogawa T; Hieda N; Sugiyama S; Toki Y; Ito T; Ogawa K; Satake T; Ozawa T
Arzneimittelforschung; 1988 Feb; 38(2):228-30. PubMed ID: 3370069
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
Björkman JA; Abrahamsson TI; Nerme VK; Mattsson CJ
Thromb Res; 2005; 116(6):519-24. PubMed ID: 16181987
[TBL] [Abstract][Full Text] [Related]
19. Myocardial salvage by a novel thromboxane A2 synthetase inhibitor in a canine coronary occlusion-reperfusion model.
Toki Y; Hieda N; Okumura K; Hashimoto H; Ito T; Ogawa K; Satake T
Arzneimittelforschung; 1988 Feb; 38(2):224-7. PubMed ID: 3370068
[TBL] [Abstract][Full Text] [Related]
20. [Development of new thrombolytic substances].
Zeymer U; Neuhaus KL
Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
